AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

Jefferies analyst Peter Welford maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £114.00.

The Israeli-American unicorn company ImmunAI has signed a multi-year cooperation agreement with the pharmaceutical giant ...

AstraZeneca (AZN) and Daiichi Sanyko (DSKYF)(DSNKY) said the FDA has accepted their application with priority review for ...

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on AZN stock, giving a Buy rating on September 30. Sachin ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...